SARASOTA, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on November 28, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on November 28, 2025, the Company’s common stock will trade on a post-split basis under the same trading symbol, “I ...

Computershare Trust Company, N.A. is acting as the exchange agent for the Reverse Stock Split. Registered stockholders holding pre-split shares of the Company's common stock are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other similar organization will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such organization's particular processes, and will not be required to take any action in co ...

Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Financial Data and Key Metrics Changes - The company held its 2025 Annual General Meeting, where various proposals were presented for stockholder voting, including a reverse stock split and reincorporation [1][2][3] - The preliminary report indicated that all proposals, including the amendment to the equity incentive plan and the issuance of shares to Streeterville Capital, were approved by a majority of votes [12][13][14][15] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed in the meeting [1][2][3] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [1][2][3] Company Strategy and Development Direction - The company proposed a reverse stock split to potentially enhance its stock price and market perception, with a range of 1-for-2 to a maximum of 1-for-10 [9][13] - The reincorporation from Delaware to Nevada was aimed at potentially benefiting from a more favorable regulatory environment [10][13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [1][2][3] Other Important Information - The meeting included the election of seven directors, with all nominated candidates successfully elected [12] - The company plans to increase the number of shares authorized for issuance under its equity incentive plan to 5 million [14] Summary of Q&A Session - No Q&A session was documented in the provided meeting records [1][2][3]

Financial Data and Key Metrics Changes - The stockholders approved the proposal to grant discretionary authority to the Board of Directors for a reverse stock split within a range of 1-for-2 to a maximum of 1-for-10, indicating a strategic move to potentially enhance share value [12][13][14] - The company successfully ratified the selection of M&K CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2025, ensuring compliance and transparency in financial reporting [15] Business Line Data and Key Metrics Changes - The amendment to the 2022 equity incentive plan to increase the number of shares authorized for issuance to 5 million was approved, which may impact employee compensation and retention strategies [14] Market Data and Key Metrics Changes - The approval of the issuance of shares to Streeterville Capital, LLC, in prepaid financing transactions that may collectively equal or exceed 20% of the issued and outstanding shares indicates a significant capital raise strategy [14] Company Strategy and Development Direction - The company is pursuing a reincorporation from Delaware to Nevada, which may provide more favorable business regulations and tax benefits [13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting, focusing instead on the proposals and voting results Other Important Information - The meeting concluded with the election of seven directors, ensuring continuity in governance and strategic direction [12][13] Summary of Q&A Session - There were no recorded questions or answers during the meeting, as the focus was primarily on the proposals and voting outcomes

Prophase Labs (NasdaqCM:PRPH) Q3 2025 Earnings Call November 19, 2025 02:00 PM ET Company ParticipantsNoella Alexander-Young - Media Relations Coordinator and Virtual Event ModeratorTed Karkus - Chairman and CEONoella Alexander-YoungHello and good afternoon, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for ProPhase Labs' third quarter 2025 r ...

MIDLAND, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or the “Company”), a technology company that provides digital infrastructure for artificial intelligence (“AI”), high-performance computing (“HPC”) and digital assets, today announced that the Company’s Board of Directors has approved the implementation of a reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock ...

Nov 17, 2025 4:25 PM Eastern Standard Time Hudson Pacific Properties Announces Reverse Stock Split Share LOS ANGELES--(BUSINESS WIRE)--Hudson Pacific Properties, Inc. ("Hudson Pacific" or the "Company") (NYSE: HPP) today announced that it will effect a 1-for-7 reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.01 per share ("Common Stock") that will become effective at 5:00 p.m. Eastern Time on December 1, 2025 (the "Effective Time"). About Hudson Pacific Properties Hudson Pac ...

Core Viewpoint - The article discusses the likelihood of stock splits among major corporations, specifically focusing on Berkshire Hathaway and Booking Holdings, suggesting that despite high share prices, these companies are unlikely to split their stocks due to their leadership philosophies and business strategies [2][3]. Group 1: Berkshire Hathaway - Berkshire Hathaway's Class A shares are priced at $761,800, indicating a strong performance and a low likelihood of a stock split, as CEO Warren Buffett prefers to attract long-term investors rather than short-term traders [4][5]. - Buffett's philosophy emphasizes stability and long-term investment, making a Class A stock split unlikely in the foreseeable future [5]. - The company has a solid foundation with a diversified portfolio and strong leadership, including the next CEO, Greg Abel, who has been with the company for over two decades [7][8][9]. Group 2: Booking Holdings - Booking Holdings has a current share price of approximately $5,100 and has previously conducted a reverse stock split in 2003, which typically indicates financial struggles [10]. - CEO Glenn Fogel has expressed reluctance towards stock splits, indicating a preference for long-term investors, which suggests that a forward split is unlikely [11]. - The company reported a 13% year-over-year revenue increase to $9 billion in Q3, with net income rising 9% to $2.7 billion, showcasing strong financial performance [12][14]. - Booking Holdings benefits from network effects, a growing travel demand, and a robust stock buyback program, making it an attractive investment regardless of potential stock splits [13][14].

Core Points - BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025 [1][2][3] - The reverse stock split was approved by stockholders at the 2025 Annual Meeting on October 16, 2025, with the final ratio set by the Board of Directors on November 13, 2025 [2] - Following the reverse stock split, the number of outstanding shares will decrease from approximately 29,006,165 to about 1,526,640 [4] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies to target specific pathogenic bacteria [5] - The company utilizes its BOLT platform to customize phage compositions aimed at treating chronic diseases with significant unmet medical needs [5]